Related Experiment Video
Updated: Aug 15, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Thrombophilia in cancer
1Hematology-Oncology Department, Ospedali Riuniti Bergamo, Bergamo, Italy. annafalanga@yahoo.com
Seminars in Thrombosis and Hemostasis
|February 12, 2005
Summary
Cancer malignancy causes a high risk of thrombosis due to a hypercoagulable state. Understanding this complex relationship is crucial for developing new therapies to prevent and treat blood clots in cancer patients.
Area of Science:
- Oncology
- Hematology
- Thrombosis Research
Background:
- Malignancy is an acquired condition that significantly increases the risk of thrombosis.
- Cancer patients exhibit a hypercoagulable state, increasing venous and arterial thromboembolism risk.
- Clotting activation may influence tumor progression, highlighting the link between thrombosis and cancer.
Purpose of the Study:
- To review the complex relationship between thrombosis and cancer.
- To explore the pathophysiology and therapeutic strategies for thrombosis in malignancy.
- To discuss the impact of clotting on cancer morbidity and mortality.
Main Methods:
- Literature review of existing research on cancer-associated thrombosis.
- Analysis of the multifactorial pathogenesis of thrombosis in cancer.
- Examination of the role of tumor cells and antitumor therapies in hemostasis.
Main Results:
- Thrombosis is a common and serious complication in cancer patients.
- Tumor cells activate the host hemostatic system, contributing to a prothrombotic state.
- Antitumor therapies can also exert prothrombotic effects.
Conclusions:
- Preventing thrombotic events is a critical clinical issue in cancer care.
- New therapeutic strategies targeting the clotting mechanism are being investigated.
- Inhibiting clotting may offer potential benefits for managing malignant disease.
Related Concept Videos
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...